Skip to main content

Table 3 NanoString PanCancer Pathways® differentially expressed genes

From: Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

mRNA

Log2 fold change

Standard error (log2)

Linear fold change

p value

Gene sets

SPP1

− 2.96

0.804

0.129

0.0017

PI3K

CDKN2A

− 2.05

0.805

0.242

0.0211

Cell cycle, apoptosis, tumor suppressor gene

CNTFR

− 1.98

0.702

0.253

0.0111

JAK-STAT

DDIT4

− 1.65

0.557

0.319

0.0848

PI3K

WNT5A

− 1.49

0.702

0.355

0.0474

Hedgehog, Wnt

ITGA9

1.01

0.36

2.02

0.0116

PI3K

LAT

1.07

0.453

2.1

0.0297

Ras

IL7R

1.08

0.427

2.11

0.0214

JAK-STAT, PI3K

PPARGC1A

1.21

0.519

2.32

0.0312

Chromatin modification

TSLP

1.23

0.544

2.34

0.0379

JAK-STAT

ID4

1.31

0.353

2.47

0.00163

TGF-β

TNR

1.33

0.602

2.52

0.0408

PI3K

RASGRP2

1.42

0.614

2.68

0.0336

MAPK, Ras

HNF1A

1.49

0.591

2.8

0.0223

Driver gene

COL2A1

1.59

0.606

3.01

0.0178

PI3K

EFNA2

1.69

0.626

3.22

0.0154

PI3K, Ras

CCR7

1.7

0.68

3.25

0.0229

Transcriptional misregulation

IL2ORB

1.71

0.607

3.26

0.0116

JAK-STAT

WNT16

1.87

0.777

3.66

0.0277

Hedgehog, transcriptional misregulation, Wnt

CALML5

2.07

0.749

4.21

0.0127

Ras

IL6

2.51

0.707

5.71

0.00244

JAK-STAT, PI3K, transcriptional misregulation

CD19

2.62

0.764

6.13

0.00323

PI3K

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us